| A First-in-human Study to Investigate Safety and Tolerability of SAR446959 in Participants With Osteoarthritis of the Knee (NCT06704932) | Sanofi | 2024-11-20 |
| An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates (NCT06686628) | Sanofi | 2024-11-20 |
| A Study to Assess Tolerability of the Trivalent Recombinant Vaccine in Individuals Aged 18 and Older Using the Vaccinees Perception of Injection Questionnaire (NCT06765187) | Sanofi | 2024-11-18 |
| Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older (NCT06695130) | Sanofi | 2024-11-18 |
| Study in Paediatric Patients With Atopic Dermatitis Treated With Dupilumab in Spain (NCT06415175) | Sanofi | 2024-11-14 |
| A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan (NCT06684314) | Sanofi | 2024-11-11 |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (NCT06676319) | Sanofi | 2024-11-07 |
| A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma (NCT06630806) | Sanofi | 2024-10-30 |
| A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (NCT05726682) | Sanofi | 2024-10-08 |
| Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma (NCT06609239) | Sanofi | 2024-09-30 |
| Registry for Stage 2 Type 1 Diabetes (NCT06481904) | Sanofi | 2024-09-27 |
| A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease (NCT06557772) | Sanofi | 2024-08-29 |
| A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (NCT06290141) | Sanofi | 2024-08-21 |
| A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies (NCT06508489) | Sanofi | 2024-08-13 |
| A Study of RSV-HMPV Bivalent Vaccine VXB-241 in Older Adults (NCT06556147) | Sanofi | 2024-08-13 |
| A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps (NCT06454240) | Sanofi | 2024-07-17 |
| A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin Lymphoma (NCT06392477) | Sanofi | 2024-07-08 |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema (NCT05897424) | Sanofi | 2024-06-20 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata (NCT06444451) | Sanofi | 2024-06-06 |
| A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis (NCT06293053) | Sanofi | 2024-05-15 |
| A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (NCT06407934) | Sanofi | 2024-05-08 |
| A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD) (NCT06192576) | Sanofi | 2024-04-16 |
| A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis. (NCT06372145) | Sanofi | 2024-04-16 |
| Implementation and Evaluation of a Rare Disease Algorithm to Identify Persons at Risk of Gaucher Disease Using Data From Electronic Health Records (EHRs) in the United States (Project Searchlight) (NCT05908656) | Sanofi | 2024-04-02 |
| A Food Effect and Relative Bioavailability Study of Rilzabrutinib in Healthy Participants (NCT06342700) | Sanofi | 2024-03-25 |
| A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab (NCT06145373) | Sanofi | 2024-03-01 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (NCT06241118) | Sanofi | 2024-02-29 |
| A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis (NCT05983068) | Sanofi | 2024-02-22 |
| A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis (NCT06280391) | Sanofi | 2024-02-20 |
| A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. (NCT06143891) | Sanofi | 2024-01-23 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids (NCT06224348) | Sanofi | 2024-01-18 |
| A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD (NCT06208306) | Sanofi | 2024-01-11 |
| Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) (NCT06191315) | Sanofi | 2024-01-03 |
| Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy (NCT06258057) | Sanofi | 2024-01-02 |
| A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine (NCT06087627) | Sanofi | 2023-12-27 |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (NCT06141486) | Sanofi | 2023-12-27 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2) (NCT06181435) | Sanofi | 2023-12-21 |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (NCT06141473) | Sanofi | 2023-12-13 |
| Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study (NCT05991323) | Sanofi | 2023-12-12 |
| Frexalimab in Preservation of Endogenous Insulin Secretion Compared to Placebo in Adults, Adolescents and Children on Top of Insulin Therapy (FABULINUS) (NCT06111586) | Sanofi | 2023-12-11 |
| A Study to Observe How Pediatric Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions Respond to Dupilumab Treatment (NCT06192563) | Sanofi | 2023-11-30 |
| A Study Assessing Esophageal Function and Remodeling With Dupilumab Compared With Placebo for 24 Weeks Followed by 104 Weeks Open Label in Adult Participants With EoE (REMOdeling With Dupilumab in Eosinophilic Esophagitis Long-term Trial) (NCT06101095) | Sanofi | 2023-11-29 |
| A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab (NCT06169527) | Sanofi | 2023-11-28 |
| A Prospective Study to Investigate Safety and Tolerability of Shorter Infusion of Fabrazyme (NCT06019728) | Sanofi | 2023-11-10 |
| Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis (NCT06058156) | Sanofi | 2023-11-09 |
| A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (NCT06130566) | Sanofi | 2023-11-08 |
| Proof-of-concept Study Evaluating Subcutaneous Amlitelimab in Adult Participants With Moderate to Severe Hidradenitis Suppurativa (NCT06118099) | Sanofi | 2023-11-01 |
| A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis (NCT06073119) | Sanofi | 2023-10-26 |
| Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France (NCT06393946) | Sanofi | 2023-10-20 |
| Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma (NCT06102005) | Sanofi | 2023-10-16 |
| Study of SAR447537 (INBRX-101) Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema (NCT05856331) | Sanofi | 2023-10-12 |
| Observational Study of Canadian Patients (6 Years or Older) Receiving Dupixent® for Moderate to Severe Atopic Dermatitis (NCT06099704) | Sanofi | 2023-10-10 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia (NCT06067425) | Sanofi | 2023-10-10 |
| A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (NCT06082037) | Sanofi | 2023-10-10 |
| A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo (NCT06015308) | Sanofi | 2023-10-06 |
| A Study to Evaluate the Quality of Life in Male and Female Adult Participants With Severe Asthma Treated With Dupilumab in a Real-world Setting (NCT06018441) | Sanofi | 2023-10-03 |
| Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24 (NCT06059456) | Sanofi | 2023-10-02 |
| Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan (NCT06052800) | Sanofi | 2023-09-13 |
| A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria (NCT05972629) | Sanofi | 2023-08-07 |
| Study Based on Electronic Health RecOrds to Identify Patients at High-risk of Fabry DiseasE (HOPE Fabry) (NCT05671770) | Sanofi | 2023-07-28 |
| Teplizumab in Pediatric Stage 2 Type 1 Diabetes (NCT05757713) | Sanofi | 2023-07-25 |
| A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A (NCT05911763) | Sanofi | 2023-06-30 |
| A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Relapsed/Refractory Acute Myeloid Leukemia (NCT05712278) | Sanofi | 2023-06-16 |
| A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566 (NCT05844735) | Sanofi | 2023-05-22 |
| Dupilumab in Chinese Adult Participants With CRSwNP (NCT05878093) | Sanofi | 2023-05-16 |
| A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) (NCT05839626) | Sanofi | 2023-05-15 |
| A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants. (NCT05858788) | Sanofi | 2023-05-15 |
| A Comparison of Extended Versus Conventional Duration of Enoxaparin Prophylaxis (i.e., Preventive Treatment) for Venous Thromboembolism (VTE, i.e., Blood Clots in the Veins) and Bleeding Event Risk in a Population With Acute Medical Illness (NCT05819112) | Sanofi | 2023-04-25 |
| Comparison of the Risk of Venous Thromboembolism (i.e., Blood Clots in the Veins) and Bleeding Events in a Population of Obese Patients Receiving Higher-Dose or Extended-Duration Versus Conventional-Dose or Conventional-Duration of Prophylaxis (i.e., Preventive Treatment) With Enoxaparin (NCT05819125) | Sanofi | 2023-04-25 |
| An Observational, Retrospective Multicentre Medical Record Review to Describe the Post-authorisation Early Clinical Experience of Dupilumab in the Treatment of Adult Severe Asthma (NCT06064526) | Sanofi | 2023-04-19 |
| International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab (NCT05669989) | Sanofi | 2023-04-05 |
| A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (NCT05704049) | Sanofi | 2023-04-05 |
| Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (NCT05769777) | Sanofi | 2023-04-03 |
| Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis (NCT06039241) | Sanofi | 2023-03-07 |
| A Randomized Controlled Trial to Compare the Glycemic Control, With or Without the Connected Solution, of Adult Type 2 Diabetic Participants on Basal Insulin in Taiwan (NCT05684341) | Sanofi | 2023-02-17 |
| A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia (NCT05662319) | Sanofi | 2023-02-01 |
| A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function (NCT05718258) | Sanofi | 2023-01-18 |
| A Pharmacokinetic and Tolerability Study of Fexinidazole in a Single Oral Dose in Adult Participants With Mild and Moderate Hepatic Impairment (NCT05607173) | Sanofi | 2023-01-18 |
| A Study to Evaluate the Quality of Life of Male and Female Adult Patients With Severe Refractory Atopic Dermatitis Treated With Dupilumab in Czech Republic (NCT05527964) | Sanofi | 2022-12-30 |
| A Study to Evaluate the Effect of SAR443820 on Serum Neurofilament Levels in Male and Female Adult Participants With Multiple Sclerosis (NCT05630547) | Sanofi | 2022-12-19 |
| A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India (NCT05628090) | Sanofi | 2022-11-30 |
| A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors (NCT05584670) | Sanofi | 2022-11-29 |
| Dupilumab Skin BArrier Function and LIpidomics STudy in Atopic Dermatitis in China (NCT05624112) | Sanofi | 2022-11-25 |
| Dose-finding Study of SAR443122 in Adult Participants With Ulcerative Colitis (NCT05588843) | Sanofi | 2022-11-25 |
| Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (NCT05468320) | Sanofi | 2022-11-21 |
| A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region (NCT05649813) | Sanofi | 2022-11-20 |
| Avalglucosidase Alfa Pregnancy Study (NCT05734521) | Sanofi | 2022-10-26 |
| A Study to Observe How Insulin Glargine 300 U/ml is Working and is Tolerated in Elderly Patients ≥75 Years of Age With Type 2 Diabetes (NCT05607160) | Sanofi | 2022-10-05 |
| Effect of Tusamitamab Ravtansine on QTc Interval in Participants With Metastatic Solid Tumors (NCT05429762) | Sanofi | 2022-10-03 |
| Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors (NCT05450562) | Sanofi | 2022-09-20 |
| A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥2 Years to <12 Years of Age With Uncontrolled Chronic Spontaneous Urticaria (CSU) (LIBERTY-CSU CUPIDKids) (NCT05526521) | Sanofi | 2022-08-25 |
| Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI) (NCT05231668) | Sanofi | 2022-08-25 |
| Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (NCT05492578) | Sanofi | 2022-08-22 |
| Real World Study on the Use of Cemiplimab in Adult Patients in UK (NCT05493826) | Sanofi | 2022-07-18 |
| A Study to Investigate Safety, Tolerability and Clinical Response With SAR441566 Compared With Placebo in Participants With Mild to Moderate Psoriasis (NCT05453942) | Sanofi | 2022-07-12 |
| iGlarLixi vs IDegAsp in Chinese Participants After OAD(s) (NCT05413369) | Sanofi | 2022-07-07 |
| Dose Ranging Study of Amlitelimab in Adult Participants With Moderate-to-severe Asthma (NCT05421598) | Sanofi | 2022-06-30 |
| SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM (NCT05405166) | Sanofi | 2022-06-23 |
| Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France (NCT05359276) | Sanofi | 2022-06-10 |
| BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR) (NCT05156710) | Sanofi | 2022-06-09 |